Skip to content
Disclosery

MWG Management Ltd.

Follow

13F filer, CIK 1845151, Washington, DC

MWG Management Ltd. reported $81,319,135 across 3 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-25-277944

Period
2025-09-30
Reported value
$81.3M
Holdings
3
Top 10 weight
100%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
LYELnew+1,008,116$16.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LYELL IMMUNOPHARMA INCexited-1,008,116-$8.91M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001193125-25-277944, largest first. % of portfolio is the value over $81,319,135, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BEAMBEAM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: 2,346,934 shares; 2024Q1: 2,346,934 shares; 2024Q2: 2,266,934 shares; 2024Q3: 2,266,934 shares; 2024Q4: 2,266,934 shares; 2025Q1: 2,266,934 shares; 2025Q2: 2,266,934 shares; 2025Q3: 2,266,934 shares 2,266,934$55M67.66%0Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,008,116 shares 1,008,116$16.4M20.13%newTimeline
PRMEPRIME MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: 1,792,210 shares; 2024Q1: 1,792,210 shares; 2024Q2: 1,792,210 shares; 2024Q3: 1,792,210 shares; 2024Q4: 1,792,210 shares; 2025Q1: 1,792,210 shares; 2025Q2: 1,792,210 shares; 2025Q3: 1,792,210 shares 1,792,210$9.93M12.21%0Timeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INC1,008,116$8.91Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-25-277944 base2025-11-12acceptance time not in the bulk data set